Motivation to change is considered an important component of treatment readiness and response among patients with addictive disorders. This process is thought to play a key role in substance abuse treatment, from recognizing the need for change, seeking treatment, responding to treatment and sustaining changes in behavior following treatment. A better understanding of how to best measure motivation to change and how motivation relates to successful behavior change among both drug and alcohol abusers would broaden our understanding of the role of motivation in the treatment of addictions.

II. METHODS

Two multi-site, randomized clinical trials involving comparisons of motivational interventions with standard care were conducted in the National Institute on Drug Abuse Clinical Trials Network (CTN). Patients with primary drug dependence and primary alcohol dependence entering outpatient substance abuse treatment participated in either a three-session Motivational Enhancement Therapy (MET) study (n=431) or a one-session Motivational Interviewing (MI) study (n=423). The construct and predictive validity of two composite measures of motivation to change derived from the University of Rhode Island Change Assessment Scale (URICA): Readiness to Change (RTC) and Committed Action (CA) were evaluated. Motivation at baseline was examined as a potential moderator of treatment outcome. Motivation at 4 weeks was also examined as a potential mediator of treatment outcome at 12 weeks.

III. MEASURES

• Motivation to Change: The University of Rhode Island Change Assessment Scale (URICA), a 32-item self-report inventory, measures patient motivation. The URICA has four subscales corresponding to the stages of change from the Transtheoretical model of behavior change: Precontemplation, Contemplation, Action, and Maintenance. The URICA was administered at baseline and four weeks after completing the single session of MI or three sessions of MET. Two composite measures of motivation were examined: Readiness to Change (RTC) and Committed Action (CA). RTC is calculated by subtracting the Precontemplation subscale score from the sum of the Contemplation, Action and Maintenance subscales (Project MATCH Research Group, 1997). CA is calculated by subtracting the Contemplation subscale score from the Action subscale score (Paneltan et al, 2002).
• Substance Use and Treatment Retention: Self-reports of substance use were collected via a substance use calendar using the timeline follow-back procedures and verified using biological measures. Treatment retention data were 3 months following completion of the study protocol and were based on self-report and verified using client records.

IV. DATA ANALYSIS

Confirmatory factor analysis was used to evaluate the a priori factor structure URICA across patient population using procedures defined by Byrne (2001).

The potential moderating effect of RTC and CA on treatment outcomes was examined using procedures defined by Aiken & West (1991). Unstandardized beta coefficients, 95% confidence intervals and p values are reported for interaction effects in the baseline models. The change in F statistic, degrees of freedom and p value are reported for subsequent models that assess the potential linear, curvilinear and main effects. The potential mediating effect of RTC and CA on treatment outcomes was evaluated using procedures defined by Kraemer et al (2002). Unstandardized beta coefficients and 95% confidence intervals are reported.

V. RESULTS

• The a priori factor structure of the URICA was confirmed across patients with primary drug and primary alcohol use. The factor structure was not invariant across groups. Differences were identified in items 11 and 15 of the Precontemplation subscale of the URICA.
• RTC was significantly associated with fewer days of drug use among patients with primary drug use and lower treatment retention among patients with primary alcohol use. CA was not significantly associated with treatment outcomes.
• Neither RTC nor CA at baseline were found to moderate treatment outcomes.
• Neither RTC nor CA at 4 weeks were found to mediate treatment outcomes.

This research was supported by a grant from the NIDA Clinical Trials Network.